Cart
sales@molnova.com
UCB7362
CAS No. 2610631-17-7
UCB7362( —— )
Catalog No. M36288 CAS No. 2610631-17-7
UCB7362 (GLXC-26743) is an orally available and potent plasmepsin X (PMX) inhibitor with anti-malarial activity.UCB7362 inhibits parasite reproduction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 880 | Get Quote |
|
| 5MG | 1207 | Get Quote |
|
| 25MG | 1822 | Get Quote |
|
| 50MG | 2374 | Get Quote |
|
| 100MG | 3060 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameUCB7362
-
NoteResearch use only, not for human use.
-
Brief DescriptionUCB7362 (GLXC-26743) is an orally available and potent plasmepsin X (PMX) inhibitor with anti-malarial activity.UCB7362 inhibits parasite reproduction.
-
DescriptionUCB7362 (GLXC-26743) is an orally available and potent plasmepsin X (PMX) inhibitor with anti-malarial activity.UCB7362 inhibits parasite reproduction.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetParasite
-
RecptorParasite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2610631-17-7
-
Formula Weight479.96
-
Molecular FormulaC25H26ClN5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@]1(CC(=O)N(C(N)=N1)[C@H]2C[C@@H](C)OCC2)C3=C(Cl)C(NC(=O)C4=CC(C#N)=CC=C4)=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Antimalarial agent 3...
Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.
-
Eflornithine
Eflornithine (DFMO) is a selective and orally available ornithine decarboxylase inhibitor that delays hair overgrowth.Eflornithine is used in the study of African trypanosomiasis, malignant glioma, and sleeping sickness.
-
Rafoxanide
A salicylanilide anthelmintic agent that also shows to be an allosteric inhibitor of SPAK and OSR1.
